No it was asked separately. Double J asked the Kevetrin MTD-MAD question and after it was answered by Dr Menon then or before Leo said before getting into the status of Kevetrin P1 in depth at Dana Farber they needed to have a meeting.
I cannot recall if that was with only DF or if the FDA would be included in that. After that meeting he would advise us of the outcome.
Market Data 
Markets 
AI
